More than 15,000 Adverse Events Linked to Xarelto in 2016
Category: Xarelto
More Info: Defective Drugs
As the number of lawsuits against the blood thinner Xarelto continues to climb, so do reports of injuries and deaths caused by the controversial anticoagulant, according to a recent study by the Institute for Safe Medication Practices (ISMP).
According to ISMP, the U.S. Food and Drug Administration received 15,043 reports of serious injury or death linked to Xarelto last year — a 41 percent increase over the previous year.
ISMP, a non-profit organization that monitors and analyzes adverse drug events reported to the government, published the findings in its annual edition of QuarterWatch.
Oral blood thinners such as Xarelto caused more emergency room visits in 2016 than any other class of drugs, ISMP found. The group said it identified nearly 22,000 reports of severe injury, including 3,018 deaths. Nearly all of the injuries were from internal bleeding, the report states. Of the five anticoagulants implicated, rivaroxaban, sold under the brand name Xarelto, accounted for 68.4 percent of all adverse events in 2016, according to ISMP.
Continue reading...
See the original article here: https://www.prnewswire.com/news-releases/report-more-than-15000-adverse-events-linked-to-xarelto-in-2016-300493860.html
About TriMark Legal Funding
TriMark Legal Funding was founded in 2003 and is one of America's leading national lawsuit funding companies. TriMark provides pre-settlement funding and post-settlement funding, sometimes called 'lawsuit loans', to injured plaintiffs throughout the United States. We offer funding on hundreds of different types of legal claims including personal injury loans, employment litigation funding, work injury accident loans, workers compensation loans, mass tort litigation funding, and multidistrict litigation funding.
We also provide immediate inheritance advance funding for heirs and beneficiaries, as well as attorney funding and law firm financing for legal practices.
Personal Injury Lawsuits | Mass Torts |
Click here to see the original article.